Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716805 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02716805 is a Phase 1 study that was terminated before completion, run by Ludwig Institute for Cancer Research. The registered enrollment target is 6 participants.
The verdict
NCT02716805, a Phase 1 study, was terminated before completion, sponsored by Ludwig Institute for Cancer Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This was a Phase 1, open-label, multicenter, study of checkpoint inhibitor therapy (tremelimumab ± durvalumab) prior to and following autologous stem cell transplant (ASCT) and high-dose melphalan in subjects with multiple myeloma who were at a high risk for relapse, were eligible for ASCT, and had available cryopreserved stem cells. Primary study objectives were to determine the safety and tolerability of study treatment. Further objectives were to evaluate the clinical efficacy and biologic activity of the regimen.
Interventions
- DRUG Melphalan
- DRUG Durvalumab
- DRUG Tremelimumab
- BIOLOGICAL Prevnar-13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2018-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716805
The ClinicalTrials.gov registry entry for NCT02716805 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT02716805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02716805 about?
NCT02716805 is a clinical study titled "Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant". This was a Phase 1, open-label, multicenter, study of checkpoint inhibitor therapy (tremelimumab ± durvalumab) prior to and following autologous stem cell transplant (ASCT) and high-dose melphalan in subjects with multiple myeloma who were at a high risk for relapse, were eligible for ASCT, and had ...
What is the current status of trial NCT02716805?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-12-13. Estimated completion is 2018-02-16.
What interventions are being tested in trial NCT02716805?
The interventions under investigation include: Melphalan (DRUG), Durvalumab (DRUG), Tremelimumab (DRUG), Prevnar-13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02716805?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.